Radiofrequenzablation von Lebertumoren mittels 4 cm Schirmelektrode

Background: The purpose of this study was to evaluate safety and efficacy of a radiofrequency ablation system in clinical practice. Methods: In 35 patients (age 63,9 ±12,6 years, range 22-83) a total of 65 liver tumors were percutaneously treated using a 200 watt radiofrequency generator and a LeVeen 4 cm array probe (RF3000, Boston Scientific). The interventions were performed under CT guidance in local anaesthesia and sedation. Adapted to the tumor size, the LeVeen Probe was repositioned during the procedure with an additional safety margin of 1 cm. Primary tumors were colorectal in 22, and mamma tumors (n = 4), zystic pancreas tumors (n = 2), gastric cancer (n = 1), zystadenocarcinoma of the liver (n = 1), lung cancer (n = 1), gastrointestinal stroma tumor (n = 1), duodenal carcinoma (n = 1), cholangiocellular carcinoma (n=1) and hepatocellular carcinoma (n = 1). Postinterventional control and follow-up was performed with multislice-CT (collimation 2.5 mm, unenhanced and contrast enhanced, arterial and portal filling) at 4 weeks, and every three months. Results: One to 4 metastases were treated per patient during one or up to 4 procedure sessions. Mean lesion size was 2,3 ± 1,2 cm (range 0,2 to 7,0).